跳至主要内容
临床试验/NCT03182413
NCT03182413已完成1 期

Therapeutic Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation in Healthy Subjects

Theranexus0 个研究点目标入组 20 人开始时间: 2015年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Theranexus
入组人数
20
主要终点
Sustained attention (PVT)

研究概览

简要总结

Study Objectives: THN102 is a new combination between modafinil and flecainide low-dose, a documented glial connexin inhibitor. Efficacy of THN102 was compared to modafinil and to placebo on parameters impaired by total sleep deprivation (SD, lasting 40h).

Methods: 20 healthy male subjects participated in a double-blind, randomised, incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo (PBO), modafinil 100 mg (MOD), and combinations THN102 (modafinil 100 mg and 1, 3 or 9 mg flecainide as THN1, THN3 and THN9), as 3 oral doses over 18h.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

PBO

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

MOD

Active Comparator

Modafinil 100mg

干预措施: Modafinil (Drug)

THN102 100/1

Experimental

modafinil 100 mg + 1 mg flecainide

干预措施: THN102 (Drug)

THN102 100/3

Experimental

modafinil 100 mg + 3 mg flecainide

干预措施: THN102 (Drug)

THN102 100/9

Experimental

modafinil 100 mg + 9 mg flecainide

干预措施: THN102 (Drug)

结局指标

主要结局

Sustained attention (PVT)

时间窗: 5 hours post treatment

Mean speed at the 10 min Psychomotor vigilance test (PVT)

次要结局

  • Working memory(16,5 hours post treatment)
  • Sustained attention (PVT) AUC(AUC of PVT speed during TSD)
  • Mental flexibility(16,5 hours post treatment)
  • Mental inhibition(16,5 hours post treatment)

研究者

发起方
Theranexus
申办方类型
Industry
责任方
Sponsor

相似试验

Impact of THN102 on Attention, Wakefulness and... | 临床试验